Endoron Medical Ltd. raised $10 million in its series A funding round to accelerate clinical validation work on its catheter-based endostapling system, Aortoseal, which repairs abdominal aortic aneurysms. The round was led by Sofinnova Partners, with participation from the European Innovation Council Fund.
In the first six months of 2024, the med-tech industry raised $13.84 billion, a 29% increase from the $10.75 billion collected during the first half of 2023. While May saw a significant $5.05 billion raised, the monthly total decreased to $1.14 billion in June.
Myricx Bio Ltd. has closed the largest series A for a European biotech this year, raising £90 million (US$115.4 million), to take forward antibody-drug conjugates based on novel payload chemistry.
Smartcella Holding AB raised €50 million (US$54 million) in a new share issue that it will use to accelerate growth and ramp up commercialization of its endovascular Extroducer delivery device, in addition to strengthening its cell and mRNA operations. The funding is supported by existing and new investors including Astrazeneca, which committed to approximately half of the shares issued.
Myricx Bio (Myricx Pharma Ltd.), a spin out from Imperial College London and the Francis Crick Institute, has closed a series A financing raising £90 million ($114 million) to support its work focused on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs).
Biopharma financings reached $70.09 billion in the first half of 2024, a 129% increase from the $30.57 billion raised in the first half of 2023. At more than $70 billion, this year's financings are already approaching the full-year total of $70.97 billion for 2023. June saw $7.57 billion in total financings, a decrease from $9.15 billion in May.
RSS
